跳至主要内容
临床试验/DRKS00023618
DRKS00023618招募中不适用

ThrombX Retriever Post Market Surveillance Study - ThrombX_R

ThrombX Medical, Inc.0 个研究点目标入组 30 人开始时间: 2021年1月20日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Age 18 to 85;
  • - Clinical signs consistent with acute anterior circulation ischemic stroke;
  • - Pre-stroke Modified Rankin Score = 2;
  • - NIHSS = 4 and < 25 immediately prior to enrollment;
  • - Imaging shows Alberta Stroke Program early computed tomography (ASPECT) score =6 with computed tomography (CT) scanning or core infarct volume <50mL on magnetic resonance imaging (MRI) or CT based perfusion imaging;
  • - Computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) shows an occlusion of the intracranial carotid or the middle cerebral artery M1 division;
  • - An appropriate signed and dated informed consent form is obtained from the patient or the patient’s legally designated representative and treating physician

排除标准

  • - Known serious sensitivity to radiographic contrast agents;
  • - Known sensitivity to nickel, titanium metals, or their alloys:
  • - Renal failure as defined by a serum creatinine > 2·0 mg/dl (or 176·8 µmol/l) or glomerular filtration rate (GFR) < 30 or Subject who requires hemodialysis or peritoneal dialysis;
  • - Baseline blood glucose of <50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol);
  • - Baseline platelet count < 50,000/uL;
  • - Presumed septic embolus; suspicion of bacterial endocarditis;
  • - Contraindication to an angiogram for any reason;
  • - Known history of arterial tortuosity, preexisting stent, or other arterial disease that would prevent the device from reaching the target vessel or preclude safe recovery of the device;
  • - Presence of carotid dissection;
  • - Imaging or clinical evidence of concomitant posterior circulation stroke or acute stroke involving both anterior circulations;
  • - CT or MRI evidence of hemorrhage or evidence of mass effect;
  • - Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate/large infarct with poor collateral circulation)

研究者

相似试验

已完成
不适用
An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolismon-small cell lung cancer, small cell lung cancer
JPRN-UMIN000020194Shimane University Faculty of Medicine1,025
已完成
不适用
An observational study for thrombus regression by anti-coagulation therapy in venous thromboembolismVenous thromboembolism
JPRN-UMIN000019910Gunma University90
尚未招募
不适用
A risk control study of thrombosis occurred just before admission to a psychiatric ward
JPRN-UMIN000010351ational Defense Medical College100
进行中(未招募)
1 期
ENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase II or III clinical study evaluating eltrombopag - LENSong-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR)MedDRA version: 8.1Level: LLTClassification code 10007739Term: Cataract
EUCTR2006-002945-36-ESGlaxoSmithKline S.A.
进行中(未招募)
不适用
ENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase II or III clinical study evaluating eltrombopag - LENSong-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR)MedDRA version: 14.1Level: PTClassification code 10007739Term: CataractSystem Organ Class: 10015919 - Eye disorders
EUCTR2006-002945-36-CZGlaxoSmithKline Research and Development Ltd800